We also have an error rate of < 0.5% for our glioma panel (AmpliSeq glioma custom panel: AKT1, ATRX, BRAF, CDKN2A, CIC, EGFR, FGFR1, H3F3A, HIST3B, IDH1, IDH2, NOTCH1, PIK3CA, PIK3R1, PTEN, PTPN11, TERT, TP53) NGS analysis. Here, CDKN2A is linked to central nervous system cancer.